About Erbi Biosystems

Erbi Biosystems, Inc. has been acquired by MilliporeSigma!

We continue to seek out talented individuals who want to help us grow our innovative cell culture products and business. Please look for opportunities to work with us on the MilliporeSigma careers page here: Careers Section | EMD Group

Erbi Biosystems supports therapeutic drug manufacturers with tools to accelerate the development of their processes and therapies. Erbi’s technology platform includes single-use, mL-scale cell culture, microfluidics, optical sensing, and integrated controls.

The Breez bioreactor is used across a range of applications and cell types, including media and cell-line development; intensified process and n-1; CAR-T process development; and non-mammalian cell culture. The small size, single-use device, and fully automated operation drastically reduce the time, media consumption and lab space required for process development. The mL-scale working volume and closed-sterile consumable format make it ideal when working with scarce and highly variable source materials, such as autologous therapy development.

The Erbi Breez system is available worldwide with sales and distribution in the US, EU, and China.

Founders

Co-Founder and CTO

Harry Lee, Ph.D.

Dr. Lee founded the company in 2006 based on his doctoral research and expanded the capability and applications of the core technology over the past 14 years.

Dr. Lee founded the company in 2006 based on his doctoral research and expanded the capability and applications of the core technology over the past 14 years. Harry has deep expertise in systems engineering, photonics, embedded systems, cell culture and bioengineering. He has a B.S.E.E. from the University of Michigan and a PhD from the Massachusetts Institute of Technology. Harry is inventor on 8 patents, is the author of multiple publications in the field and has been awarded multiple grants to further develop Erbi’s core technology.
Head of Cell & Gene Therapy & Bioprocess Applications Development

Kevin Lee, Ph.D.

Dr. Lee formally joined Erbi as co-founder in 2011 but helped develop the core technology platform with Dr. Harry Lee as part of his doctoral research,

Dr. Lee formally joined Erbi as co-founder in 2011 but helped develop the core technology platform with Dr. Harry Lee as part of his doctoral research, which included design of continuous flow microbioreactors and development of a proprietary and patented plastic bonding process that is an enabling technology in Erbi’s bioreactor platform. Kevin also is expert in embedded systems, cell culture and bioengineering and has a B.S.E.E. from the University of California, Los Angeles and a PhD from the Massachusetts Institute of Technology. Kevin is inventor on 6 patents, and has led programs with industry and academia across multiple cell types including e.coli, Pichia, CHO and CAR-T.